Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Apartment Investment and Management Co (AIV) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance

Apartment Investment and Management CoTrade
Citius Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Apartment Investment and Management Co vs Citius Pharmaceuticals Inc — how do they compare? Apartment Investment and Management Co trades at $2.61 (market cap $376.16M), while Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M). The key difference: Apartment Investment and Management Co is far larger — about 18.8× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is trading nearer its 52-week high, Apartment Investment and Management Co nearer its low. Which is the better fit depends on your goals.

AIVCTXR
Market Cap
$376.16M$20.01M
Sector
Real EstateHealth
52-Week High
$7.93$1.82
52-Week Low
$2.59$0.48
Enterprise Value
$738.32M$16.23M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Apartment Investment and Management Co

AIV trades at $2.605, down 0.57% on the day, with a bearish technical outlook showing 13 sell signals on moving averages. The stock presents a mixed fundamental picture with a strong 400% net income margin and 228% ROE for 2025, though revenue declined to $138M from $209M in 2024. Recent earnings show volatility with two beats and two misses in the last four quarters. The company announced a $1.30 dividend for H1-2026, payable in June 2026.

AIV offers value with a P/B ratio of 0.76 and positive cash flow generation, but faces challenges from declining revenue and inconsistent earnings performance. The bearish technical setup and mixed analyst sentiment (33% buy, 67% hold) suggest cautious optimism. Key risks include execution volatility and real estate sector headwinds, while the dividend provides income support.

Citius Pharmaceuticals Inc

CTXR is trading at $0.765, up 13.0% in the past 24 hours, with a bullish technical signal from moving averages. The company shows strong analyst support with 83% buy ratings but faces significant financial challenges including negative earnings, a -823.34% net income margin, and consecutive quarterly EPS misses. Recent news highlights expansion of LYMPHIR cancer treatment commercialization with 78% quarterly growth in new institutional accounts.

While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial losses and negative cash flow from operations present significant investment risks. The company's ability to achieve profitability through its oncology drug commercialization will determine long-term shareholder value creation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Apartment Investment and Management Co

Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment

Read more on AIV

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR